ANGO - AngioDynamics, Inc.
After hours:
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 9.41 |
| Open | 9.41 |
| Bid | 9.49 x 1800 |
| Ask | 9.48 x 800 |
| Day's Range | 9.28 - 9.54 |
| 52 Week Range | 8.18 - 24.74 |
| Volume | |
| Avg. Volume | 338,850 |
| Market Cap | 371.176M |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings Date | Jul 10, 2023 - Jul 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.50 |
Fair Value
Related Research
ZacksNew Strong Sell Stocks for May 18th
ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.
ZacksZacks.com featured highlights include Dutch Bros, Chegg, Impinj and AngioDynamics
Dutch Bros, Chegg, Impinj and AngioDynamics are part of the Zacks Screen of the Week article.
ZacksIs the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
ZacksSell These 4 Toxic Stocks to Prevent Portfolio Losses
The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.
ZacksZacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva
AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.
- Zacks
4 Toxic Stocks That Are Detrimental to Your Portfolio's Health
Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
Business WireAngioDynamics to Present at the Needham Virtual Healthcare Conference
LATHAM, N.Y., April 11, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Needham 22nd Annual Virtual Healthcare Conference at 8:00
ZacksImplied Volatility Surging for AngioDynamics (ANGO) Stock Options
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Motley FoolWall Street Thinks This Small-Cap Stock Can Double in Value
This arguably was demonstrated when shares of medical device maker AngioDynamics (NASDAQ: ANGO) plummeted 27% on the day of its fiscal third-quarter earnings release recently. With a $400 million market capitalization, AngioDynamics is one of the smaller publicly traded medical device companies. AngioDynamics' product lineup includes NanoKnife, a minimally invasive treatment utilized in patients with inoperable or late-stage cancers.
Insider MonkeyAngioDynamics, Inc. (NASDAQ:ANGO) Q3 2023 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2023 Earnings Call Transcript March 30, 2023 Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. […]
ZacksAngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
ZacksAngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireAngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance
LATHAM, N.Y., March 30, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2023, which ended February 28, 2023.
Simply Wall St.Shareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested a year ago
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
Business WireAngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023
LATHAM, N.Y., March 13, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same da
Business WireAngioDynamics to Participate in Three Investor Conferences in March
LATHAM, N.Y., February 28, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in the following three investor conferences in March:
- Zacks
Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Motley FoolIs This Under-the-Radar Growth Stock a Buy?
Within that last group sits AngioDynamics (NASDAQ: ANGO), a little-known company that makes devices for treating peripheral vascular disease. Let's dig into AngioDynamics' fundamentals and valuation to address this question. With a market capitalization of just $539 million, AngioDynamics is a medtech business that flies under the radar of most retail investors.
Insider MonkeyAngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call Transcript January 5, 2023 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.01. Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Second Quarter Earnings Call. At this time all participants are in listen-only-mode. A question-and-answer session will follow the formal presentation. As […]
- Simply Wall St.
AngioDynamics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
AngioDynamics ( NASDAQ:ANGO ) Second Quarter 2023 Results Key Financial Results Revenue: US$85.4m (up 9.1% from 2Q...
- Zacks
AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
American City Business JournalsAngioDynamics revenue jumps 9.1% as hospital staff shortages continue to impact sales
The Latham manufacturer is in the midst of a multiyear shift away from lower-margin legacy products as CEO Jim Clemmer has refocused the business around the development higher-margin technology to combat blood clots and tumors.
ZacksAngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireAngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance
LATHAM, N.Y., January 05, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2023, which ended November 30, 2022.
ZacksSARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?
SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.